Top

Gepubliceerd in:

01-06-2003 | Artikelen

Epidemiologie van mammacarcinoomepidemiologie

Auteur: Dr. M. A. Rookus

Gepubliceerd in: Bijblijven | Uitgave 6/2003

Samenvatting

Nederland behoort tot de landen waarin mammacarcinoom het meest voorkomt. In 1998 werd de ziekte bij 10.317 vrouwen gediagnosticeerd en 3542 vrouwen overleden eraan. Terwijl de incidentie de laatste decennia fors is toegenomen is de mortaliteit nagenoeg constant gebleven, met een mogelijk lichte daling in de laatste tien jaar. De stijgende incidentie hangt deels samen met veranderende risicofactoren en deels met het bevolkingsonderzoek. Dat de mortaliteit desondanks zo opmerkelijk stabiel is gebleven lijkt te kunnen worden toegeschreven aan een gunstiger stadium bij diagnose en een verbeterde behandeling (o.a. met tamoxifen).

Mammacarcinoom hangt slechts voor 30-50% samen met bekende risicofactoren. Bekende en vermoede determinanten van borstkanker zijn: reproductieve factoren (leeftijd menarche en menopauze, pariteit, borstvoeding, leeftijd geboorte eerste kind), hormoongebruik (hormonale substitutie, orale anticonceptie), overgewicht, een eerdere goed- of kwaadaardige borstaandoening, alcohol, voeding (mogelijk: mono-onverzadigde vetzuren, sojaproducten, groente en fruit), lichamelijke activiteit en genetische factoren. Mogelijk zijn ook in utero factoren of factoren op jonge leeftijd van belang.

vorige artikel Mammacarcinoom en huisarts

volgende artikel Diagnostiek van mammaklachten in relatie tot het mammacarcinoom

Visser O, Coebergh JWW, Dijck JAAM van, Siesling S (eds). Incidence of cancer in the Netherlands 1998. Utrecht: Association of Comprehensive Cancer Centers, 2002.

Pike MC, Spicer DV, Dalimoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Revs 1993;15:48-65.

Coebergh JW, Janssen M, Louwman M. Voogd A. Cancer incidence, care and survival in the South of the Netherlands, 1955-1999. Eindhoven: Comprehensive Cancer Center South, 2001.

Otto SJ, Francheboud J, Looman CWN et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003;361:1411-7.CrossRefPubMed

Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, Vol. VIII, IARC Scientific Publications No. 155. Lyon, Frankrijk: IARC, 2002.

Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Revs 1993;15:36-48.

Willett WC, Rockhill B, Hankinson SE, et al. Epidemiology and nongenetic causes of breast cancer. In: Diseases of the breast, 2nd ed. Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Philadelphia PA: Lippincott Williams & Wilkins, 2000.

Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet 2001;2:133-40.CrossRef

Kliewer E, Smith K. Breast cancer mortality among immigrants in Australia and Canada. J Natl Cancer Inst 1995;97:1154-61.

Bouchardy C. Cancer in Italian migrant populations: France. IARC Sci Publ 1993;123:149-59.PubMed

Thomas DB, Karagas MR. Cancer in first and second generation Americans. Cancer Research 1987;47:5771-6.PubMed

Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Eng J Med 2002;346:1609-15.CrossRefPubMed

Lambe M, Hsieh C, Trichopoulos D, et al. Transient increase in risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.CrossRefPubMed

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360(9328):187-95.

Melbey M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. New Engl J Med 1997;336:81-5.CrossRef

Key TJ, Verkasalo PK. Endogenous hormones and the aetiology of breast cancer. Breast Cancer Res 1999;1:18-21.CrossRefPubMed

Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998 Sep 2;90(17):1292-9.CrossRefPubMed

Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998 May 9;351(9113):1393-6.CrossRefPubMed

Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999 Apr 7;91(7):629-34.CrossRefPubMed

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347(9017):1713-27.

Anderson TJ, Battersby S, King RJB, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139-44.CrossRefPubMed

Williams G, Anderson E, Howell A, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 1991;48:206-10.CrossRefPubMed

Rookus MA, Leeuwen FE van. Het effect van de pil op borstkanker. In: Pil over pil. Everdingen JJE van, Bleker OP, Lunsen HW van (eds). Overveen: Belvedere/Medidact, 2001.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350(9084):1047-59.

Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.

Beral V, Blanks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002;260:942-4.CrossRef

Writing group for the women's health initiative investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.

Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. New Eng J Med 2003;348:1839-54.CrossRefPubMed

Malone KE. Diethylstilbestrol (DES) and breast cancer. Epidemiologic Rev 1993;15:108-9.

Claus EB, Schildkraut J, Iversen ES, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. JNCI 1998;90:1824-9.PubMed

Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68(2):410-9.CrossRefPubMed

Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18(2):173-90.CrossRefPubMed

Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94(18):1365-72.PubMed

Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998;63(1):45-51.CrossRefPubMed

Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68(3):700-10.CrossRefPubMed

Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91(14):1241-7.CrossRefPubMed

Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer: a pooled analysis. N Engl J Med 1996;334:356-61.CrossRefPubMed

Willett WC Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am J Clin Nutr 1997;66[suppl]:1557s-63s.PubMed

Key TJ, Sharp GB, Appleby PN, et al. Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 1999;81:1248-56.CrossRefPubMed

Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer – Collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002;87(11):1234-45.

Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11.CrossRefPubMed

Brandt PA van den, Speigelman D, Yaun S, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.CrossRefPubMed

Berglund G. Anthropometry, physical activity and cancer of the breast and colon. IARC Sci Publ 2002;156:237-41.PubMed

Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet 1990 Apr 21;335(8695):939-40.CrossRefPubMed

Ekbom A, Trichopoulos D, Adami HO, et al. Evidence of prenatal influences on breast cancer risk. Lancet 1992 Oct 24;340(8826):1015-8.CrossRefPubMed

Johnson TW, Anderson KE, Lazovich D, et al. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002 Dec;11(12):1586-91.PubMed

Lillberg K, Verkasalo PK, Kaprio J, et al. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol. 2003 Mar 1;157(5):415-23.CrossRefPubMed

Lanting CI, Herschderfer K, Wouwe JP van, et al. Peiling melkvoeding van zuigelingen 2001/2002 en het effect van certificering op de borstvoedingscijfers. TNO rapport 2002-309, 2002.

Waard F. de. Guest editorial – Responding to the challenge of breast cancer. Prim Prev Breast Cancer 2002;4:115-6.

Titel: Epidemiologie van mammacarcinoomepidemiologie
Auteur: Dr. M. A. Rookus
Publicatiedatum: 01-06-2003
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 6/2003
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/BF03059716

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2003

Diagnostiek van mammaklachten in relatie tot het mammacarcinoom

Effectiviteit van bevolkingsonderzoek naar borstkanker

Mammacarcinoom en huisarts

Erfelijke vormen van mammacarcinoomerfelijk carcinoom

Endocriene therapie van mammacarcinoom

Chirurgische therapie: nieuwe ontwikkelingenchirurgie